Early and Late Side Effects and Patient Management in I-131 Treatment
Journal Title: Nuclear Medicine Seminars - Year 2021, Vol 7, Issue 1
Abstract
I-131 is the first most experienced theranostic radionuclide that has been used since the early 1940s for the treatment of hyperthyroidism, metastases or ablation of residual thyroid tissue in well-differentiated thyroid cancers. Although generally safe and very well tolerated, radioiodine therapy has some potential side effects classified as early and late complications. Early side effects include nausea, rarely vomiting, oral mucositis, sialadenitis, taste disturbance, gastrointestinal, gonadal and hematopoietic system dysfunction and radiation thyroiditis in the cases with large residual tissue. Late complications include secondary cancers, pulmonary fibrosis, and permanent bone marrow suppression. Early complications are generally due to the radioiodine activity and have transient nature, late complications are due to the cumulative radiation dose and are rare. The aim of this article is to review the potential side effects and complications of I-131 therapy and their clinical management.
Authors and Affiliations
Mehmet Reyhan
Keywords
Related Articles
- EP ID EP693443
- DOI 10.4274/nts.galenos.2021.0009
- Views 103
- Downloads 0
Developments in Pain Imaging
In order to determine the etiology of chronic pain, radiological imaging tools like computed tomography (CT) and magnetic resonance imaging (MRI) are usually used. Except for the anatomical data that the radiological ima...
Nephrourologic Imaging: Yesterday, Today, Tomorrow
Renal function measurement and renal imaging using radionuclidic methods have a long history. Since 1950s, estimation of glomerular function and tubular function were possible using several radiopharmaceuticals. Later, s...
Good Radiopharmacy Practice (GRP): Personnel and Training
Radiopharmaceuticals are medical products that are used for diagnosis and/or treatment in humans and containing one or more radionuclides (radioisotopes). The shelf life and expiry period of the radiopharmaceutical prepa...
The Use of F-18-FDG PET/CT in Renal and Bladder Tumors
Clinical imaging has been the cornerstone to guide patient management and therapy strategies for oncology patients. In the last decades, the use of fluorodeoxyglucose positron emission tomography/computed tomography (PET...
Practical Guidance on Peptide Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT) have been successfully used for the past 20 years to target metastatic or inoperable neuroendocrine tumors expressing the somatostatin receptors. Both prospective and retrospe...